Drug Type Monoclonal antibody |
Synonyms SY101 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 2 | CN | 01 Aug 2018 |